Compare Match Group Inc (MTCH) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Match Group Inc vs Summit Therapeutics Inc — how do they compare? Match Group Inc trades at $41.52 (market cap $9.53B), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Match Group Inc pays a 1.93% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Match Group Inc for 115 Days and Summit Therapeutics Inc for 16 Days on average.
| MTCH | SMMT | |
|---|---|---|
Market Cap | $9.53B | $13.71B |
Volume | 3,228,794 | 6,173,057 |
Sector | Media | Health |
52-Week High | $44.40 | $26.38 |
52-Week Low | $28.90 | $12.43 |
Typical Hold Time | 115 Days | 16 Days |
Enterprise Value | $12.49B | $13.04B |
Dividend Yield | 1.93% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MTCH trades at $41.48, up 1.52% today, near the consensus price target of $42.29. The stock shows a bullish technical trend with strong moving averages, though RSI indicates potential overbought conditions. Fundamentally, the company maintains robust profitability with a 20.17% net income margin and positive cash flow trends, while recent earnings have been mixed with a beat in Q2 2026 but a miss in Q1 2026. Positive sentiment is driven by product innovation at Tinder and growth from Hinge.
The outlook for MTCH is positive, supported by analyst consensus leaning buy (53% of ratings) and a projected EPS beat in Q3 2026. Investment opportunities include margin expansion and AI-driven product enhancements, but risks involve high debt levels and competitive pressures in the dating app market. Shareholder value may benefit from sustained cash flow generation and strategic initiatives.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
